NASDAQ$THRD
Third Harmonic Bio Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Third Harmonic Q1 2025 Earnings Report
Third Harmonic Bio, Inc. reported a net loss of $15.834 million for the three months ended March 31, 2025, an increase from $7.856 million in the same period last year. The company's total operating expenses significantly increased to $18.716 million, primarily driven by higher research and development costs.
- Net loss increased to $15.834 million in Q1 2025 from $7.856 million in Q1 2024.
- Total operating expenses rose to $18.716 million in Q1 2025 from $11.290 million in Q1 2024, a 66% increase.
- Research and development expenses increased by 71% to $10.645 million in Q1 2025, mainly due to the THB335 program.
- General and administrative expenses increased by 59% to $8.071 million in Q1 2025, driven by personnel-related expenses and stock-based compensation.
Headline financials
Revenue & EPS history
Third Harmonic · Revenue · Quarterly
$0
Forward guidance
The company expects its existing cash and cash equivalents to be sufficient to fund operations and capital expenses through at least 2026, subject to stockholder approval of the Dissolution and Plan of Dissolution. They plan to complete Phase 2 readiness activities for THB335 by mid-year 2025 to maximize its value for a potential asset sale.
Tailwinds
- Existing cash and cash equivalents are expected to fund operations through at least 2026.
- Completion of Phase 2 readiness activities for THB335 by mid-year 2025 to maximize asset sale value.
- Potential for future funding through equity offerings, debt financings, or collaborations.
- Ability to establish and maintain collaborations, strategic partnerships, or marketing arrangements.
- Potential for obtaining regulatory approval for THB335 and future product candidates.
Headwinds
- Significant increase in net losses for the foreseeable future.
- Substantial additional funding may be required, which may not be available on acceptable terms or at all.
- Failure to obtain necessary capital could delay or terminate product development programs.
- Uncertainty in predicting the timing and amount of increased expenses.
- Potential for dilution of ownership interests if additional capital is raised through equity issuance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports · overlaid with Q1 2025
+1.0%
Avg return
Earnings day
+14.2%
Avg return
5 days after
+13.0%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+13.0%
Q3 2024
Best reaction
-11.1%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +0.6% | -0.2% | +5.8% | |
| Q4 2024 | -1.1% | +42.1% | +41.9% | |
| Q3 2024 | +13.0% | +13.0% | -11.2% | |
| Q2 2024 | +10.6% | +11.5% | +9.2% | |
| Q1 2024 | +10.2% | +11.8% | +3.3% | |
| Q4 2023 | +8.0% | +7.1% | +29.2% | |
| Q3 2023 | +0.8% | — | — | |
| Q2 2023 | -6.4% | — | — | |
| Q1 2023 | -11.1% | — | — | |
| Q4 2022 | -3.5% | — | — | |
| Q3 2021 | -1.2% | — | — | |
| Q4 2021 | -1.2% | — | — | |
| Q3 2022 | -1.2% | — | — | |
| Q1 2022 | -1.2% | — | — | |
| Q2 2022 | -1.2% | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro